Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Golidocitinib Versus Placebo as Maintenance Therapy in Peripheral T-Cell Lymphoma Patients With Response (CR/PR) After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial

NCT07414758 is registered in ClinicalTrials.gov with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT07414758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07414758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Golidocitinib Versus Placebo as Maintenance Therapy in Peripheral T-Cell Lymphoma Patients With Response (CR/PR) After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial
Lead sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Phase 3
Overall status
Recruiting
Start date
February 15, 2026
Completion date
September 30, 2029
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t cell lymphoma